Placebo News and Research

RSS

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICAR for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal.

28 Jun 2011

New and effective diabetes drug seeking approval

A new drug for diabetes from Bristol-Myers Squibb Co. and AstraZeneca PLC was effective in lowering blood sugar. The pharmaceutical drug makers are looking for approval for the drug, dapagliflozin, as the first in new class of pills designed to lower blood sugar by increasing the amount of glucose excreted in the urine.

27 Jun 2011

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed dosing the first patient in Part B of the ongoing Phase I study.

27 Jun 2011

Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease

Mimetogen Pharmaceuticals Inc. today announced positive top line data from the Phase II clinical trial of MIM-D3 for dry eye disease. The trial demonstrated statistically significant improvements in signs and symptoms with its low (1%) and high (5%) doses of MIM-D3, together with excellent safety and tolerability profiles.

27 Jun 2011

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Dr Seizaburo Kashiwagi presented the preliminary data from an influenza Phase III prophylaxis study conducted during the 2009/2010 pandemic flu season in Japan.

27 Jun 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.

27 Jun 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011

Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced Phase III study results for linagliptin, demonstrating improved glycaemic control in adults with type 2 diabetes (T2D) whose blood glucose is not adequately maintained.

27 Jun 2011

Positive preliminary findings from ATI's neurostimulation system study on cluster headache

Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable system for severe headaches, today announced positive preliminary findings from a study evaluating the safety and efficacy of the company's investigational neurostimulation system for the treatment of cluster headache.

27 Jun 2011

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

27 Jun 2011

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.

27 Jun 2011

Promising results from MGH's BCG Phase I trial on type I diabetes

Promising results of the Phase I clinical trial of the generic drug BCG to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego.

27 Jun 2011

Intravenous diclofenac holds promise against severe pain following oral surgery

An essential aspect of oral surgery is controlling the patient's pain following a procedure. The goal is to relieve pain and promote a rapid recovery, without opioid side effects. An initial study shows that Dyloject, a new intravenous form of the drug diclofenac, has promise for achieving these goals.

27 Jun 2011

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced new data from a Phase 1b study of ZGN-433, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed a significant improvement in cardiovascular risk markers in severely obese subjects.

27 Jun 2011

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

24 Jun 2011

EMA CHMP recommends approval of linagliptin for type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes.

24 Jun 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

$Inhaled corticosteroids linked to increased risk of fractures in patients with COPD$

Inhaled corticosteroids linked to increased risk of fractures in patients with COPD

Patients with chronic obstructive pulmonary disease (COPD) who use inhaled corticosteroids to improve breathing for more than six months have a 27 percent increased risk of bone fractures, new Johns Hopkins-led research suggests.

24 Jun 2011

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.

24 Jun 2011

Oxytocin hormone holds promise for children with Prader-Willi syndrome

Prader-Willi syndrome is a rare genetic disorder which affects one child in 25,000. Children born with this syndrome have a range of complex neurological and developmental problems which continue into adult life. These can manifest as cognitive and behavioral difficulties, weight gain, problems in controlling their temper and attendant difficulties in socialization.

24 Jun 2011

Placebo News and Research

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

New and effective diabetes drug seeking approval

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes

Positive preliminary findings from ATI's neurostimulation system study on cluster headache

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

Promising results from MGH's BCG Phase I trial on type I diabetes

Intravenous diclofenac holds promise against severe pain following oral surgery

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

EMA CHMP recommends approval of linagliptin for type 2 diabetes

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Inhaled corticosteroids linked to increased risk of fractures in patients with COPD

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Oxytocin hormone holds promise for children with Prader-Willi syndrome

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News